ELYM צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Eliem Therapeutics

Quarterly net income per share dynamics for Eliem Therapeutics (ELYM) demonstrate the impact of patent protection and the TenCentri deal, with the parameter value equal to -826.10. The company's revenues are based on the development of therapies for depression, epilepsy, and pain syndromes. Business growth relies on the expertise of leading neurobiologists, who are attracted by innovative developments and high bonuses for successful tests.
פילוחים אנליטיים של חברת Eliem Therapeutics

This metric reflects the dynamics of net earnings per share, serving as a measure of fundamental business stability through the analysis of quarterly growth. By analyzing the quarterly EPS trajectory on the GURU.Markets platform, an investor can see the results of cost optimization, which for Eliem Therapeutics (ELYM) is confirmed by the implementation of ESG standards and the reduction of chemical waste in biotechnological research of the nervous system.